Moleculin Biotech (NASDAQ:MBRX) resumed with Outperform rating and $2 (94% upside) price target at Oppenheimer. Shares up 4% after hours.
Vertex Pharmaceuticals (NASDAQ:VRTX) resumed with Buy rating and $220 (25% upside) price target at BofA Merrill Lynch.
Regeneron Pharmaceuticals (NASDAQ:REGN) resumed with Neutral rating and $325 (9% upside) price target at BofAML.
Merck (NYSE:MRK) resumed with Neutral rating and $90 (7% upside) price target at BofAML.
Pfizer (NYSE:PFE) resumed with Neutral rating and $37 (2% upside) price target at BofAML.
Eli Lilly (NYSE:LLY) resumed with a Buy rating and $133 (23% upside) price target at BofAML.
Gilead Sciences (NASDAQ:GILD) resumed with Neutral rating and $70 (7% upside) price target at BofAML.
Bristol-Myers Squibb (NYSE:BMY) resumed with Buy rating and $60 (16% upside) price target at BofAML.
BioMarin Pharmaceutical (NASDAQ:BMRN) resumed with Buy rating and $90 (32% upside) price target at BofAML. Shares up 1% after hours.
Amgen (NASDAQ:AMGN) resumed with Neutral rating and $215 (6% upside) price target at BofAML.
Biogen (NASDAQ:BIIB) resumed with Underperform rating and $200 (12% downside risk) price target at BofAML. Shares down a fraction after hours.
https://seekingalpha.com/news/3506336-bofa-merrill-lynch-sees-25-percent-upside-vertex-hours-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.